{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T09:12:13Z","timestamp":1793437933784,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"vor","delay-in-days":101,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Reports"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.toxrep.2021.04.003","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T18:36:15Z","timestamp":1618943775000},"page":"871-879","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"special_numbering":"C","title":["Safety of COVID-19 vaccines administered in the EU: Should we be concerned?"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2983-5418","authenticated-orcid":false,"given":"Antonio F.","family":"Hern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1523-9116","authenticated-orcid":false,"given":"Daniela","family":"Calina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Poulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca Oana","family":"Docea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristidis M.","family":"Tsatsakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.toxrep.2021.04.003_bib0005","first-page":"1631","article-title":"A new threat from an old enemy: re emergence of coronavirus (Review)","volume":"45","author":"Docea","year":"2020","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.toxrep.2021.04.003_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.toxrep.2020.12.001","article-title":"Improved strategies to counter the COVID-19 pandemic: lockdowns vs. primary and community healthcare","volume":"8","author":"Farsalinos","year":"2021","journal-title":"Toxicol. Rep."},{"issue":"6","key":"10.1016\/j.toxrep.2021.04.003_bib0015","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s12026-020-09154-4","article-title":"Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development","volume":"68","author":"Calina","year":"2020","journal-title":"Immunol. Res."},{"key":"10.1016\/j.toxrep.2021.04.003_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2020.111418","article-title":"COVID-19, an opportunity to reevaluate the correlation between long-term effects of anthropogenic pollutants on viral epidemic\/pandemic events and prevalence","volume":"141","author":"Tsatsakis","year":"2020","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.toxrep.2021.04.003_bib0025","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.toxrep.2021.03.005","article-title":"COVID-19 pandemic and alcohol consumption: impacts and interconnections","volume":"8","author":"Calina","year":"2021","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.toxrep.2021.04.003_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2020.111769","article-title":"SARS-CoV-2 pathophysiology and its clinical implications: an integrative overview of the pharmacotherapeutic management of COVID-19","volume":"146","author":"Tsatsakis","year":"2020","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.toxrep.2021.04.003_bib0035","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.toxrep.2020.12.013","article-title":"Nicotinic cholinergic system and COVID-19: In silico evaluation of nicotinic acetylcholine receptor agonists as potential therapeutic interventions","volume":"8","author":"Alexandris","year":"2020","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.toxrep.2021.04.003_bib0040","series-title":"Interim Clinical Guidance for Management of Patients With Confirmed Coronavirus Disease (COVID-19)","author":"CDC (Centers for Disease Control and Prevention)","year":"2021"},{"key":"10.1016\/j.toxrep.2021.04.003_bib0045","series-title":"Coronavirus Cases: 5th April 2021","author":"Worldometer","year":"2021"},{"key":"10.1016\/j.toxrep.2021.04.003_bib0050","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.16462","article-title":"Back to basics in COVID-19: antigens and antibodies-Completing the puzzle","author":"Neagu","year":"2021","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.toxrep.2021.04.003_bib0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2020.4596","article-title":"Towards effective COVID 19 vaccines: updates, perspectives and challenges (Review)","volume":"46","author":"Calina","year":"2020","journal-title":"Int. J. Mol. Med."},{"issue":"5","key":"10.1016\/j.toxrep.2021.04.003_bib0060","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4155\/tde-2016-0006","article-title":"mRNA vaccine delivery using lipid nanoparticles","volume":"7","author":"Reichmuth","year":"2016","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.toxrep.2021.04.003_bib0065","article-title":"Development of multi-epitope peptide-based vaccines against SARS-CoV-2","author":"Lim","year":"2020","journal-title":"Biomed. J."},{"issue":"2","key":"10.1016\/j.toxrep.2021.04.003_bib0070","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3390\/pharmaceutics13020206","article-title":"Lipid nanoparticles as delivery systems for RNA-based vaccines","volume":"13","author":"Aldosari","year":"2021","journal-title":"Pharmaceutics"},{"issue":"10249","key":"10.1016\/j.toxrep.2021.04.003_bib0075","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"issue":"10275","key":"10.1016\/j.toxrep.2021.04.003_bib0080","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.toxrep.2021.04.003_bib0085","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41577-020-00480-0","article-title":"Viral targets for vaccines against COVID-19","volume":"21","author":"Dai","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.toxrep.2021.04.003_bib0090","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","article-title":"SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates","volume":"6","author":"Kyriakidis","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.toxrep.2021.04.003_bib0095","series-title":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Assessment Report \u2013 Comirnaty (Pfizer\/BioNTech). 19 February 2021 EMA\/707383\/2020","author":"EMA","year":"2021"},{"key":"10.1016\/j.toxrep.2021.04.003_bib0100","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.addr.2020.12.008","article-title":"Non-viral COVID-19 vaccine delivery systems","volume":"169","author":"Park","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.toxrep.2021.04.003_bib0105","series-title":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Assessment Report \u2013 COVID-19 Vaccine Moderna. 11 March 2021 EMA\/15689\/2021","author":"EMA","year":"2021"},{"issue":"5","key":"10.1016\/j.toxrep.2021.04.003_bib0110","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.toxrep.2021.04.003_bib0115","series-title":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Assessment Report \u2013 COVID-19 Vaccine AstraZeneca. 29 January 2021 EMA\/94907\/2021","author":"EMA","year":"2021"},{"key":"10.1016\/j.toxrep.2021.04.003_bib0120","series-title":"Eurpean Medicines Agency. AstraZeneca\u2019s COVID-19 Vaccine: EMA Finds Possible Link to Very Rare Cases of Unusual Blood Clots With Low Blood Platelets Statement Issued on April 4th, 2021","author":"EMA","year":"2021"},{"key":"10.1016\/j.toxrep.2021.04.003_bib0125","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","author":"Greinacher","year":"2021","journal-title":"New Engl J Med."},{"key":"10.1016\/j.toxrep.2021.04.003_bib0130","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","author":"Schultz","year":"2021","journal-title":"New Engl J Med."},{"issue":"26","key":"10.1016\/j.toxrep.2021.04.003_bib0135","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.1182\/blood-2010-06-292938","article-title":"Heparin modifies the immunogenicity of positively charged proteins","volume":"116","author":"Chudasama","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.toxrep.2021.04.003_bib0140","article-title":"Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH","author":"Oldenburg","year":"2021","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.toxrep.2021.04.003_bib0145","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26132","article-title":"Thrombocytopenia following pfizer and moderna SARS-CoV-2 vaccination","author":"Lee","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.toxrep.2021.04.003_bib0150","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12959-021-00263-0","article-title":"Pathological findings in rotation thromboelastometry associated with thromboembolic events in COVID-19 patients","volume":"19","author":"Boss","year":"2021","journal-title":"Thromb. J."},{"key":"10.1016\/j.toxrep.2021.04.003_bib0155","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.toxrep.2020.04.012","article-title":"Editorial: nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system","volume":"7","author":"Farsalinos","year":"2020","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.toxrep.2021.04.003_bib0160","first-page":"1","article-title":"Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review","author":"Jenner","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.toxrep.2021.04.003_bib0165","series-title":"Coronavirus Vaccine - Weekly Summary of Yellow Card Reporting","author":"MHRA (Medicines & Healthcare products Regulatory Agency)","year":"2021"},{"key":"10.1016\/j.toxrep.2021.04.003_bib0170","doi-asserted-by":"crossref","first-page":"102125","DOI":"10.1016\/j.scr.2020.102125","article-title":"Neutralizing antibodies targeting SARS-CoV-2 spike protein","volume":"50","author":"Xiaojie","year":"2020","journal-title":"Stem Cell Res."},{"issue":"2","key":"10.1016\/j.toxrep.2021.04.003_bib0175","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41418-020-00720-9","article-title":"COVID-19 Commission of Accademia Nazionale dei Lincei, Rome. COVID-19 vaccines: where we stand and challenges ahead","volume":"28","author":"Forni","year":"2021","journal-title":"Cell Death Differ."},{"issue":"371","key":"10.1016\/j.toxrep.2021.04.003_bib0180","article-title":"Covid-19: people with history of significant allergic reactions should not receive Pfizer vaccine, says regulator","author":"Mahase","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.toxrep.2021.04.003_bib0185","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.toxrep.2020.10.016","article-title":"Vaccine- and natural infection-induced mechanisms that could modulate vaccine safety","volume":"7","author":"Kostoff","year":"2020","journal-title":"Toxicol. Rep."},{"key":"10.1016\/j.toxrep.2021.04.003_bib0190","series-title":"3\u00ba Informe de Farmacovigilancia sobre Vacunas COVID-19","author":"AEMPS - Agencia Espa\u00f1ola de Medicamentos y productos sanitarios (AEMPS)","year":"2021"},{"issue":"2","key":"10.1016\/j.toxrep.2021.04.003_bib0195","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.0830","article-title":"Sequelae in adults at 6 months after COVID-19 infection","volume":"4","author":"Logue","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.toxrep.2021.04.003_bib0200","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01283-z","article-title":"Post-acute COVID-19 syndrome","author":"Nalbandian","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.toxrep.2021.04.003_bib0205","series-title":"Pharmacovigilance Plan of the EU Regulatory Network for COVID-19 Vaccines","author":"EMA","year":"2020"},{"key":"10.1016\/j.toxrep.2021.04.003_bib0210","doi-asserted-by":"crossref","DOI":"10.1126\/science.abg3055","article-title":"Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England","author":"Davies","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.toxrep.2021.04.003_bib0215","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(21)00143-2","article-title":"Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study","author":"Moore","year":"2021","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.toxrep.2021.04.003_bib0220","doi-asserted-by":"crossref","first-page":"8","DOI":"10.7150\/ijbs.52569","article-title":"Current advances in the development of SARS-CoV-2 vaccines","volume":"17","author":"Awadasseid","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.toxrep.2021.04.003_bib0225","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1051\/mmnp\/2020045","article-title":"COVID-19 pandemic control: balancing detection policy and lockdown intervention under ICU sustainability*","volume":"15","author":"Charpentier","year":"2020","journal-title":"Math. Model. Nat. Phenom."},{"key":"10.1016\/j.toxrep.2021.04.003_bib0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2020.12.014","article-title":"Coronavirus 2019 infectious disease epidemic: where we are, what can be done and hope for","author":"Carbone","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.toxrep.2021.04.003_bib0235","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(21)00079-7","article-title":"The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation","author":"Sandmann","year":"2021","journal-title":"Lancet Infect. Dis."}],"updated-by":[{"DOI":"10.1016\/j.toxrep.2021.12.007","type":"expression_of_concern","label":"Expression of concern","source":"retraction-watch","updated":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"record-id":"37225"},{"DOI":"10.1016\/j.toxrep.2021.08.011","type":"correction","label":"Correction","source":"retraction-watch","updated":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"record-id":"37226"},{"DOI":"10.1016\/j.toxrep.2021.08.011","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000}}],"container-title":["Toxicology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214750021000792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214750021000792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:12:16Z","timestamp":1780416736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214750021000792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":47,"alternative-id":["S2214750021000792"],"URL":"https:\/\/doi.org\/10.1016\/j.toxrep.2021.04.003","relation":{},"ISSN":["2214-7500"],"issn-type":[{"value":"2214-7500","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of COVID-19 vaccines administered in the EU: Should we be concerned?","name":"articletitle","label":"Article Title"},{"value":"Toxicology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxrep.2021.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}